This study evaluates the dose response of ACT-541468 on the change of wake after sleep onset (WASO) assessed by polysomnography (PSG) on the first 2 days of each treatment period.
The study consists of 3 phases: a screening phase, a double-blind treatment phase consisting of 5 periods, and a safety follow-up phase. Safety is monitored throughout the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
58
Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg
Capsules for oral administration matching the ACT-541468 capsules
Investigator Site
Brandon, Florida, United States
Investigator Site
Chicago, Illinois, United States
Investigator Site
Las Vegas, Nevada, United States
Investigator Site
New York, New York, United States
Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2
WASO is the time in minutes spent awake after onset of persistent sleep until lights on as determined by polysomnography (PSG)
Time frame: Baseline to Day 1 and Day 2 of each treatment period
Change in Mean Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2
LPS is the duration of time in minutes from lights off to persistent sleep onset as determined by PSG
Time frame: Baseline to Day 1 and Day 2 of each treatment period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Investigator Site
Cincinnati, Ohio, United States
Investigator Site
Berlin, Germany
Investigator Site
Berlin, Germany
Investigator Site
Hamburg, Germany
Investigator Site
Hanover, Germany
Investigator Site
Schwerin, Germany